|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Steeg PS: Metastasis suppressors alter the
signal transduction of cancer cells. Nat Rev Cancer. 3:55–63. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Peltomäki P: Role of DNA mismatch repair
defects in the pathogenesis of human cancer. J Clin Oncol.
21:1174–1179. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yun J, Rago C, Cheong I, Pagliarini R,
Angenendt P, Rajagopalan H, Schmidt K, Willson JK, Markowitz S,
Zhou S, et al: Glucose deprivation contributes to the development
of KRAS pathway mutations in tumor cells. Science. 325:1555–1559.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim TM, Laird PW and Park PJ: The
landscape of microsatellite instability in colorectal and
endometrial cancer genomes. Cell. 155:858–868. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bostick M, Kim JK, Estève PO, Clark A,
Pradhan S and Jacobsen SE: UHRF1 plays a role in maintaining DNA
methylation in mammalian cells. Science. 317:1760–1764. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fidler IJ: Critical determinants of
metastasis. Semin Cancer Biol. 12:89–96. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li L, Dong X, Leong MC, Zhou W, Yang Z,
Chen F, Bao Y, Jia W and Hu R: Identification of the novel protein
FAM172A, and its up-regulation by high glucose in human aortic
smooth muscle cells. Int J Mol Med. 26:483–490. 2010.PubMed/NCBI
|
|
9
|
Li LX, Tao Z, Dong XH, Liang WC, Yang ZH,
Mou B, Bao YQ, Wang C, Jia WP and Hu RM: Molecular cloning of a
novel gene, C5orf21 gene and its roles in diabetic macroangiopathy.
Zhonghua Yi Xue Za Zhi. 89:2574–2577. 2009.(In Chinese). PubMed/NCBI
|
|
10
|
Cui C, Ye L, Huang Z, Huang S, Liu H and
Yu J: FAM172A is a tumor suppressor in colorectal carcinoma. Tumour
Biol. 37:6501–6510. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qian K, Zhang J, Lu J, Liu W, Yao X, Chen
Q, Lu S, Xiang G and Liu H: FAM172A modulates apoptosis and
proliferation of colon cancer cells via STAT1 binding to its
promoter. Oncol Rep. 35:1273–1280. 2016.PubMed/NCBI
|
|
12
|
Babashah S and Soleimani M: The oncogenic
and tumour suppressive roles of microRNAs in cancer and apoptosis.
Eur J Cancer. 47:1127–1137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Place RF, Li LC, Pookot D, Noonan EJ and
Dahiya R: MicroRNA-373 induces expression of genes with
complementary promoter sequences. Proc Natl Acad Sci USA. 105:pp.
1608–1613. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hobert O: Gene regulation by transcription
factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu M and Chen H: The role of microRNAs in
colorectal cancer. J Genet Genomics. 37:347–358. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Michael MZ, O'Connor SM, van Holst
Pellekaan NG, Young GP and James RJ: Reduced accumulation of
specific microRNAs in colorectal neoplasia. Mol Cancer Res.
1:882–891. 2003.PubMed/NCBI
|
|
24
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:pp. 2257–2261.
2006; View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cekaite L, Rantala JK, Bruun J, Guriby M,
Agesen TH, Danielsen SA, Lind GE, Nesbakken A, Kallioniemi O, Lothe
RA, et al: MiR-9, −31, and −182 deregulation promote proliferation
and tumor cell survival in colon cancer. Neoplasia. 14:868–879.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Valeri N, Braconi C, Gasparini P, Murgia
C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat
F, et al: MicroRNA-135b promotes cancer progression by acting as a
downstream effector of oncogenic pathways in colon cancer. Cancer
Cell. 25:469–483. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rokavec M, Öner MG, Li H, Jackstadt R,
Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, et
al: IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated
colorectal cancer invasion and metastasis. J Clin Invest.
124:1853–1867. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang F, Yang YZ, Shi CZ, Zhang P, Moyer
MP, Zhang HZ, Zou Y and Qin HL: UHRF1 promotes cell growth and
metastasis through repression of p16(ink4a) in colorectal cancer.
Ann Surg Oncol. 19:2753–2762. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Colangelo T, Polcaro G, Ziccardi P, Pucci
B, Muccillo L, Galgani M, Fucci A, Milone MR, Budillon A,
Santopaolo M, et al: Proteomic screening identifies calreticulin as
a miR-27a direct target repressing MHC class I cell surface
exposure in colorectal cancer. Cell Death Dis. 7:e21202016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou L, Liang X, Zhang L, Yang L, Nagao N,
Wu H, Liu C, Lin S, Cai G and Liu J: MiR-27a-3p functions as an
oncogene in gastric cancer by targeting BTG2. Oncotarget.
7:51943–51954. 2016.PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
De Bacco F, Luraghi P, Medico E, Reato G,
Girolami F, Perera T, Gabriele P, Comoglio PM and Boccaccio C:
Induction of MET by ionizing radiation and its role in
radioresistance and invasive growth of cancer. J Natl Cancer Inst.
103:645–661. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Spizzo R, Nicoloso MS, Croce CM and Calin
GA: SnapShot: MicroRNAs in cancer. Cell. 137:586–586.e1. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee HJ, Song IC, Yun HJ, Jo DY and Kim S:
CXC chemokines and chemokine receptors in gastric cancer: From
basic findings towards therapeutic targeting. World J
Gastroenterol. 20:1681–1693. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shen W, Xi H, Wei B and Chen L: The
prognostic role of matrix metalloproteinase 2 in gastric cancer: A
systematic review with meta-analysis. J Cancer Res Clin Oncol.
140:1003–1009. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu Y, Liu H, Luo X, Deng J, Pan Y and
Liang H: Overexpression of SMYD3 and matrix metalloproteinase-9 are
associated with poor prognosis of patients with gastric cancer.
Tumour Biol. 36:4377–4386. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Adiseshaiah P, Vaz M, Machireddy N,
Kalvakolanu DV and Reddy SP: A Fra-1-dependent, matrix
metalloproteinase driven EGFR activation promotes human lung
epithelial cell motility and invasion. J Cell Physiol. 216:405–412.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Belguise K, Kersual N, Galtier F and
Chalbos D: FRA-1 expression level regulates proliferation and
invasiveness of breast cancer cells. Oncogene. 24:1434–1444. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y and
Zheng X: miR-34a inhibits migration and invasion by down-regulation
of c-Met expression in human hepatocellular carcinoma cells. Cancer
Lett. 275:44–53. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Westermarck J and Kähäri VM: Regulation of
matrix metalloproteinase expression in tumor invasion. FASEB J.
13:781–792. 1999.PubMed/NCBI
|
|
41
|
Staudt LM: Oncogenic activation of
NF-kappaB. Cold Spring Harb Perspect Biol. 2:a0001092010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ben-Neriah Y and Karin M: Inflammation
meets cancer, with NF-κB as the matchmaker. Nat Immunol.
12:715–723. 2011. View Article : Google Scholar : PubMed/NCBI
|
